Pacific Biomarkers, WuXi PharmaTech Ink Biomarker Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biomarkers will provide access to its validated biomarker assays to WuXi PharmaTech under a collaboration announced today.

As part of the deal, Pacific Biomarkers will provide its biomarkers to support Shanghai-based WuXi's integrated clinical trial testing services, including bioanalysis and central laboratory services for drugmakers and biotech firms doing clinical drug development in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.